Results 1 to 10 of about 15,048 (225)
Pharmaceuticals, 2022 Nitroimidazole represents one of the most essential and unique scaffolds in drug discovery since its discovery in the 1950s. It was K. Maeda in Japan who reported in 1953 the first nitroimidazole as a natural product from Nocardia mesenterica with ...
Rohit Singh +2 more
exaly +5 more sources
Design, Synthesis and Anticancer Evaluation of Nitroimidazole Radiosensitisers
Molecules, 2023 The role of hypoxic tumour cells in resistance to radiotherapy, and in suppression of immune response, continues to endorse tumour hypoxia as a bona fide, yet largely untapped, drug target.
Lydia P. Liew +6 more
doaj +2 more sources
Structure-enabled enhancement of potency in a metronidazole–benznidazole hybrid: design, synthesis, and evaluation of antitrypanosomal activity of a benzylamide-linked 5-nitroimidazole [PDF]
Frontiers in PharmacologyBenznidazole (1) remains the primary antiparasitic drug used clinically for Chagas disease, underscoring the need to discover novel treatments targeting Trypanosoma cruzi (T. cruzi) infection.
Afonso Santine M. M. Velez +8 more
doaj +2 more sources
Prevalence of Nitroimidazole-Refractory Giardiasis Acquired in Different World Regions, Sweden, 2008–2020 [PDF]
Emerging Infectious DiseasesTreatment-refractory giardiasis is an emerging clinical problem. Of 4,285 giardiasis cases identified during 2008–2020 in Stockholm, Sweden, 102 (2.4%) were nitroimidazole refractory. Among cases acquired in India, the percentage was high (64/545 [12%])
Karin A. Ydsten +3 more
doaj +2 more sources
Antioxidants, 2023 Cellular adaptations to hypoxia promote resistance to ionizing radiation (IR). This presents a challenge for treatment of head and neck cancer (HNC) that relies heavily on radiotherapy.
Faisal Bin Rashed +5 more
doaj +1 more source
Molecules, 2022 Nitro-containing compounds are a well-known class of anti-infective agents, especially in the field of anti-parasitic drug discovery. HAT or sleeping sickness is a neglected tropical disease caused by a protozoan parasite, Trypanosoma brucei.
Alireza Mousavi +5 more
doaj +1 more source
Niclosamide Is Active In Vitro against Mycetoma Pathogens
Molecules, 2021 Redox-active drugs are the mainstay of parasite chemotherapy. To assess their repurposing potential for eumycetoma, we have tested a set of nitroheterocycles and peroxides in vitro against two isolates of Madurella mycetomatis, the main causative agent ...
Abdelhalim B. Mahmoud +5 more
doaj +1 more source
Fexinidazole for Human African Trypanosomiasis, the Fruit of a Successful Public-Private Partnership
Diseases, 2022 After 100 years of chemotherapy with impractical and toxic drugs, an oral cure for human African trypanosomiasis (HAT) is available: Fexinidazole. In this case, we review the history of drug discovery for HAT with special emphasis on the discovery, pre ...
Sonja Bernhard +3 more
doaj +1 more source
Chemosensitization by lipophilic nitroimidazoles [PDF]
British Journal of Cancer, 1983 We have carried out experiments to determine the response of tumours and normal tissues in the C3H mouse to the combination of lipophilic nitroimidazoles and CCNU, cyclophosphamide or melphalan. The nitroimidazoles studied were Ro 07-1902 (1902) and benznidazole (Ro 07-1051, BENZO). Maximum enhancement of CCNU response in the KHT sarcoma by 2.5 mmol kg-
P R, Twentyman, P, Workman
openaire +2 more sources
The Role of Nitroreductases in Resistance to Nitroimidazoles [PDF]
Biology, 2021 Antimicrobial resistance is a major challenge facing modern medicine, with an estimated 700,000 people dying annually and a global cost in excess of $100 trillion. This has led to an increased need to develop new, effective treatments. This review focuses on nitroimidazoles, which have seen a resurgence in interest due to their broad spectrum of ...
Carol Thomas, Christopher D. Gwenin
openaire +3 more sources